Orphan Drug Designation: A Strategic Guide to the EMA & MHRA Pathways
Orphan Drug Designation: A Strategic Guide to the EU & UK Pathways
For companies developing treatments for rare diseases, Orphan Drug Designation (ODD) is one of the most powerful strategic assets available. It’s not just a label; it’s a critical tool that unlocks significant financial and regulatory incentives.
However, following Brexit, navigating the ODD landscape has become more complex. Companies must now seek separate designations from both the EMA in Europe and the MHRA in the UK. This guide breaks down and compares both pathways to help you build your strategy.
A Quick Refresher: What is an Orphan Drug Designation?
Orphan Drug Designation is a formal status granted to a medicine intended for the diagnosis, prevention, or treatment of a rare, life-threatening, or chronically debilitating condition.
The primary purpose of ODD is to incentivize development in areas of high unmet medical need that would otherwise be commercially unviable. The main reward for this is a grant of 10 years of market exclusivity upon approval.
The EU Pathway: Applying to the EMA
In the European Union, the ODD process is managed by the European Medicines Agency (EMA) and its Committee for Orphan Medicinal Products (COMP). A single application to the EMA covers all 27 EU member states.
Key Criteria for EMA ODD:
- Prevalence: The condition must not affect more than 5 in 10,000 people in the European Union.
- Condition: The condition must be life-threatening or chronically debilitating.
- Justification: You must prove that either
- (a) no satisfactory method of diagnosis, prevention, or treatment exists, or
- (b) if one does exist, your product will provide a “significant benefit” to those affected.
Key Benefits in the EU:
- 10 years of market exclusivity in the EU post-approval
- (plus a 2-year extension for a completed Paediatric Investigation Plan, or PIP).
- Fee reductions for EMA services, including full fee waivers for Scientific Advice (Protocol Assistance) and reduced MAA fees.
- Access to the Centralised Procedure for your MAA.
The UK Pathway Post-Brexit: Applying to the MHRA
Since January 1, 2021, Great Britain (England, Scotland, Wales) has its own independent ODD process managed by the MHRA. The criteria are very similar to the EU’s but are applied specifically to the GB population.
Key Criteria for MHRA ODD:
- Prevalence: The condition must not affect more than 5 in 10,000 people in Great Britain (GB).
- Condition: The condition must be life-threatening or chronically debilitating.
- Justification: You must prove that either
- (a) no satisfactory method exists in GB, or
- (b) your product provides a “significant benefit” over existing treatments available in GB.
Key Benefits in the UK:
- 10 years of market exclusivity in Great Britain post-approval.
- Fee waivers for MHRA Scientific Advice and reduced fees for the marketing authorisation application.
- Potential eligibility for the ILAP (Innovative Licensing and Access Pathway).
EMA vs. MHRA Orphan Designation: Key Differences
|
|
|
|
Geography |
27 EU Member States |
Great Britain (England, Scotland, Wales) |
|
Prevalence |
< 5 in 10,000 in EU |
< 5 in 10,000 in GB |
|
“Significant Benefit” |
Compared to treatments authorised in EU |
Compared to treatments authorised in GB |
|
Application Body |
Committee for Orphan Medicinal Products (COMP) |
MHRA |
|
Market Exclusivity |
10 years in EU |
10 years in GB |
|
NI Protocol |
EMA ODD applies in Northern Ireland |
MHRA ODD does not apply in Northern Ireland |
Strategic Implications: A Dual Application is Now Essential
The most critical takeaway is that these designations are not interchangeable. An EMA ODD does not apply in Great Britain, and an MHRA ODD does not apply in the EU.
For any company serious about both markets, a dual-track strategy is now essential. Applications must be prepared and filed with both the EMA and the MHRA in parallel. This requires careful management, as the “significant benefit” justification may differ slightly based on the approved treatments in each jurisdiction.
The Northern Ireland Consideration
Due to the Windsor Framework (NI Protocol), medicines regulation in Northern Ireland remains aligned with the EU. This means an EMA Orphan Designation is valid in Northern Ireland, while an MHRA designation is not. This creates significant complexity for companies planning a single UK-wide launch and must be factored into your strategy.